Clinical Trial Update: Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an mRNA immunotherapy for Epstein-Barr virus–related refractory malignant tumors; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Malignancies

Snippet

Sponsor: West China Hospital | Conditions: Malignant Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING